Breaking the Silence: Tackling Liver Fibrosis in MASH: Who to Treat With Novel Therapies

<div class="box"> <div class="code"><span lang="EN-US" style= "font-size: 11.0pt; line-height: 115%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;" xml:lang="EN-US"><span style="font-size: 12pt;">Do you know whom to treat and why? Learn about identifying and treating at-risk metabolic dysfunction-associated steatohepatitis (MASH).</span></span><br /> <br /> Credit available for this activity expires: 11/25/2026<br /> Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/breaking-silence-tackling-liver-fibrosis-mash-who-treat-2025a1000waj?ecd=bdc_podcast_libsyn_mscpedu"> https://www.medscape.org/viewarticle/breaking-silence-tackling-liver-fibrosis-mash-who-treat-202...